GR2303
/ Genrix Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 01, 2025
A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
New P1 trial
1 to 1
Of
1
Go to page
1